Core Insights - President Trump announced agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1-based obesity and diabetes drugs and expand Medicare and Medicaid coverage starting mid-2026 [1][3] Group 1: Agreements and Pricing - Eli Lilly and Novo Nordisk will provide GLP-1 medications to Medicare and Medicaid for $245 per month, with Medicare patients paying a $50 copay for approved drugs [3] - Initial costs for existing injectables like Wegovy and Zepbound will be $350 per month, decreasing to $245 within two years [4] - Upcoming oral versions are expected to be priced at $145 per month through Medicare, Medicaid, or TrumpRx once approved [4] Group 2: Coverage and Eligibility - The initiative will start as a Medicare Part D pilot program, covering about 6.6 million Medicare enrollees with obesity or related health risks [5][6] - Eligibility will focus on individuals with obesity, prediabetes, heart disease, or kidney complications [6] Group 3: Company Developments - Eli Lilly will receive relief from potential new tariffs and be exempt from additional drug pricing programs under the Trump administration [6] - Eli Lilly announced additional price cuts on its LillyDirect platform, reducing Zepbound's price to $299 per month for the lowest dose [7] - Eli Lilly's Phase 2 trial of eloralintide showed significant weight reductions, with plans to initiate Phase 3 studies by year-end [8]